@article{f2794297c5b94c138b6e2b1d7a118ec8,
title = "Corrigendum: N0332 phase 2 trial of weekly irinotecan hydrochloride and docetaxel in refractory metastatic breast cancer: A North Central Cancer Treatment Group (NCCTG) Trial (Ann Oncol (2010) 21 (493–497) DOI: 10.1093/annonc/mdp328)",
abstract = "The following funding statement was missing from the original manuscript: {\textquoteleft}Supported by NIH grant U10CA025224 to the North Central Cancer Treatment Program.{\textquoteright} This has now been amended in the online version.",
author = "Tan, {W. W.} and Hillman, {D. W.} and M. Salim and Northfelt, {D. W.} and Anderson, {D. M.} and Stella, {P. J.} and R. Niedringhaus and Bernath, {A. M.} and Gamini, {S. S.} and F. Palmieri and Perez, {E. A.}",
note = "Funding Information: The following funding statement was missing from the original manuscript: {\textquoteleft}Supported by NIH grant U10CA025224 to the North Central Cancer Treatment Program.{\textquoteright} This has now been amended in the online version. Publisher Copyright: {\textcopyright} 2018 The Author(s). All rights reserved.",
year = "2018",
month = oct,
doi = "10.1093/annonc/mdx811",
language = "English (US)",
volume = "29",
pages = "493--497",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "10",
}